• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缩瞳剂:副作用及避免方法

Miotics: side effects and ways to avoid them.

作者信息

Zimmerman T J, Wheeler T M

出版信息

Ophthalmology. 1982 Jan;89(1):76-80. doi: 10.1016/s0161-6420(82)34866-6.

DOI:10.1016/s0161-6420(82)34866-6
PMID:7070779
Abstract

Pilocarpine, a parasympathomimetic drug used in the treatment of glaucoma, produces a variety of ocular and systemic adverse reactions. Ocular side effects include miosis, accommodative spasm, frontal headaches, twitching lids, conjunctival injection, cataractous changes, allergic reactions, iris cysts, retinal detachment, increased permeability of the blood-aqueous barrier, anterior chamber narrowing, and the potential for inducing an acute angle-closure attack. Systemic side effects include nausea, vomiting, tenesmus, abdominal spasm, salivation, lacrimation, sweating, pulmonary edema, and bronchial spasm. The systemic side effects can best be minimized initially through proper use of the medication and nasolacrimal occlusion. The Ocusert, a long-acting pilocarpine-incorporated ocular insert, is a recent advance in delivery technique that offers an adequate hypotensive action with fewer side effects. Pilopex is a promising new experimental pilocarpine polymer salt presently being studied in Israel. Photomydriasis, a process involving the use of a laser to enlarge miotic pupils also offers help for these patients. N-demethylated carbachol is a new parasympathomimetic drug currently under study for glaucoma therapy. Initial results show that it may have considerable ocular hypotensive action with fewer adverse effects.

摘要

毛果芸香碱是一种用于治疗青光眼的拟副交感神经药物,会产生多种眼部和全身不良反应。眼部副作用包括瞳孔缩小、调节痉挛、额头痛、眼睑抽搐、结膜充血、白内障改变、过敏反应、虹膜囊肿、视网膜脱离、血-房水屏障通透性增加、前房变窄以及诱发急性闭角型青光眼发作的可能性。全身副作用包括恶心、呕吐、里急后重、腹部痉挛、流涎、流泪、出汗、肺水肿和支气管痉挛。最初通过正确使用药物和鼻泪管阻塞可最大程度减少全身副作用。Ocusert是一种长效含毛果芸香碱的眼内植入物,是给药技术的一项最新进展,能提供足够的降压作用且副作用较少。Pilopex是一种有前景的新型实验性毛果芸香碱聚合物盐,目前正在以色列进行研究。光散瞳术,即一种使用激光扩大缩瞳的瞳孔的方法,也为这些患者提供了帮助。N-去甲基卡巴胆碱是一种目前正在研究用于青光眼治疗的新型拟副交感神经药物。初步结果表明,它可能具有相当大的降眼压作用且副作用较少。

相似文献

1
Miotics: side effects and ways to avoid them.缩瞳剂:副作用及避免方法
Ophthalmology. 1982 Jan;89(1):76-80. doi: 10.1016/s0161-6420(82)34866-6.
2
Miotic drugs: a review of ocular, visual, and systemic complications.缩瞳药物:眼部、视觉及全身并发症综述
Am J Optom Physiol Opt. 1976 Feb;53(2):70-80.
3
Glaucoma, miotic therapy and cataract. 3. Visual loss due to lens changes in glaucoma eyes treated with paraoxon (Mintacol), echothiophate (phospholine iodide) or pilocarpine.青光眼、缩瞳疗法与白内障。3. 使用对氧磷(米塔可)、碘依可酯(碘化磷酰硫胆碱)或毛果芸香碱治疗青光眼时因晶状体变化导致的视力丧失。
Acta Ophthalmol (Copenh). 1968;46(4):831-45. doi: 10.1111/j.1755-3768.1968.tb02883.x.
4
Miotics.缩瞳药
Br J Ophthalmol. 1968 Dec;52(12):936-7. doi: 10.1136/bjo.52.12.936.
5
[Systemic manifestations associated with the use of miotic eyedrops (parasympathomimetic substances and anticholinesterases)].
Bull Soc Belge Ophtalmol. 1979;186:9-19.
6
[Adverse effects of local medical treatment in glaucoma].
Annee Ther Clin Ophtalmol. 1968;19:79-108.
7
[Effect of myotic loading on the state of the anterior part of the eye and its reaction to anti-glaucoma surgery].
Vestn Oftalmol. 1972;3:40-1.
8
Pharmacological therapy for glaucoma: a review.青光眼的药物治疗:综述
Drugs. 2000 Mar;59(3):411-34. doi: 10.2165/00003495-200059030-00003.
9
Anticholinesterase drugs and cataracts.抗胆碱酯酶药物与白内障
Trans Am Ophthalmol Soc. 1966;64:204-16.
10
Retinal detachments and topical ocular miotics.视网膜脱离与局部眼用缩瞳剂
Ophthalmology. 1979 Jan;86(1):95-8. doi: 10.1016/s0161-6420(79)35529-4.

引用本文的文献

1
Horseshoe Retinal Tear Minutes After Use of a New Pilocarpine Formulation in a Presbyopic, Emmetropic Man.在一名老视、正视男性使用新的毛果芸香碱制剂数分钟后出现马蹄形视网膜裂孔
J Vitreoretin Dis. 2024 May 31;9(1):105-108. doi: 10.1177/24741264241255589. eCollection 2025 Jan-Feb.
2
Efficacy of combined administration of Baekhogainsam-Tang and low-dose pilocarpine on frequent intractable xerostomia: Study protocol for a randomized controlled trial.白芍甘草汤联合小剂量毛果芸香碱治疗频发难治性口干症的疗效:一项随机对照试验研究方案。
PLoS One. 2024 Nov 11;19(11):e0307557. doi: 10.1371/journal.pone.0307557. eCollection 2024.
3
An updated systematic review of pharmacological treatments for presbyopia.
一篇关于老花眼药物治疗的最新系统综述。
Adv Ophthalmol Pract Res. 2024 Sep 3;4(4):220-225. doi: 10.1016/j.aopr.2024.09.001. eCollection 2024 Nov-Dec.
4
Pilocarpine in the Treatment of Presbyopia: Progress, Issues, and Future Prospects.毛果芸香碱治疗老视:进展、问题与未来前景。
Drugs Aging. 2024 Nov;41(11):897-906. doi: 10.1007/s40266-024-01155-4. Epub 2024 Oct 26.
5
Effects of Miosis on the Visual Acuity Space under Varying Conditions of Contrast and Ambient Luminance in Presbyopia.瞳孔缩小对老花眼在不同对比度和环境亮度条件下视力空间的影响。
J Clin Med. 2024 Feb 21;13(5):1209. doi: 10.3390/jcm13051209.
6
Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia.利用谷歌搜索趋势评估公众对治疗老花眼的 Vuity 的兴趣和关注。
PLoS One. 2023 Oct 26;18(10):e0293066. doi: 10.1371/journal.pone.0293066. eCollection 2023.
7
Microwave-Assisted Synthesis of 3-Hydroxy-2-oxindoles and Pilot Evaluation of Their Antiglaucomic Activity.微波辅助合成 3-羟基-2-氧吲哚并化合物及其抗青光眼活性的初步评价。
Int J Mol Sci. 2023 Mar 7;24(6):5101. doi: 10.3390/ijms24065101.
8
Pharmacological Treatments for Presbyopia.治疗老花眼的药物疗法。
Drugs Aging. 2023 Feb;40(2):105-116. doi: 10.1007/s40266-022-01002-4. Epub 2023 Jan 20.
9
A Combined Intervention of Single Vision Plus Lens and Tropicamide in the Treatment of Pseudomyopia: A Perspective Case Report from Nepal.单光加光镜片联合托吡卡胺治疗假性近视:尼泊尔的一例前瞻性病例报告
Beyoglu Eye J. 2022 Aug 5;7(3):247-251. doi: 10.14744/bej.2022.44127. eCollection 2022.
10
Pharmacological Therapy for Presbyopia in Patients with Previous Corneal Refractive Surgery: A Pilot Study.既往接受角膜屈光手术患者老视的药物治疗:一项试点研究。
Ophthalmol Ther. 2020 Dec;9(4):1003-1010. doi: 10.1007/s40123-020-00301-6. Epub 2020 Sep 23.